Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Small Molecule Therapeutics

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically

Lucy C. Riches, Antonio G. Trinidad, Gareth Hughes, Gemma N. Jones, Adina M. Hughes, Andrew G. Thomason, Paul Gavine, Andy Cui, Stephanie Ling, Jonathan Stott, Roger Clark, Samantha Peel, Pendeep Gill, Louise M. Goodwin, Aaron Smith, Kurt G. Pike, Bernard Barlaam, Martin Pass, Mark J. O'Connor, Graeme Smith and Elaine B. Cadogan
Lucy C. Riches
1Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio G. Trinidad
1Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gareth Hughes
1Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gareth Hughes
Gemma N. Jones
2Translational Medicine, Oncology R&D, Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adina M. Hughes
1Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adina M. Hughes
Andrew G. Thomason
1Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew G. Thomason
Paul Gavine
1Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andy Cui
1Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andy Cui
Stephanie Ling
3Quantitative Biology, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Stott
3Quantitative Biology, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Clark
3Quantitative Biology, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samantha Peel
3Quantitative Biology, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pendeep Gill
1Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise M. Goodwin
1Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aaron Smith
4DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kurt G. Pike
5Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kurt G. Pike
Bernard Barlaam
5Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bernard Barlaam
Martin Pass
6Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. O'Connor
1Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark J. O'Connor
Graeme Smith
1Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elaine B. Cadogan
1Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: elaine.cadogan@astrazeneca.com
DOI: 10.1158/1535-7163.MCT-18-1394 Published January 2020
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    AZD0156 inhibits ATM signaling and potentiates the effects of irradiation. A, FaDu WT and KO cells were pretreated with increasing doses of AZD0156 for 1 hour prior to receiving 5 Gy irradiation (IR). After 1 hour, whole-cell lysates were generated, and phosphorylation of ATM substrates and DNA-PKcs was measured by Western blotting. B, FaDu WT cells were pretreated with 30 nmol/L AZD0156 or DMSO for 1 hour prior to irradiation (5 Gy). After 4 hours, cells were fixed and stained with γH2AX antibody. Images were captured on the Cell Insight, and the percent of cells with greater than five nuclear foci, as measured by Hoechst staining, was recorded. Data represent the mean of two independent experiments conducted in triplicate ± SEM. Images depict γH2AX foci in green and nuclear staining by Hoechst in blue. C, Chemical structure of AZD0156, KU-55933, and KU-60019.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    AZD0156 inhibits ATM signaling and potentiates the effects of irradiation. A, FaDu WT and KO cells were pretreated +/− 30 nmol/L AZD0156 prior to irradiation. After 7 to 10 days, colonies were scored. Data are represented as the mean of two independent experiments conducted in triplicate ± SD for FaDu WT cells and a single experiment conducted in triplicate for FaDu KO cells. B, NCI-H4441 lung cells were pretreated with increasing doses of AZD0156 for 1 hour prior to receiving 2 Gy irradiation. After 14 days, colonies were scored. Data are represented as the mean of two independent experiments conducted in duplicate ± SD. C, NCI-H441 non–small cell lung cancer xenograft grown subcutaneously was treated with 5 days of targeted irradiation (2 Gy over 2 minutes daily) combined with 38 days of once daily oral dosing AZD0156 10 mg/kg, AZD0156 administered 1 hour prior to irradiation (IR; initial group sizes n = 9–12). PO, orally; QD, every day.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    AZD0156 impairs olaparib-induced activation of ATM and potentiates the activity of olaparib in vitro. A, Cells were treated with olaparib +/− 30 nmol/L AZD0156 for 2 to 6 hours. pATM-S1981 and pCHK2-T68 were measured as markers of ATM signaling by Western blotting. B, Cells were treated with 30 nmol/L AZD0156 (red) or DMSO (black) and increasing doses of olaparib. After 7 to 10 days, colonies were scored and the surviving fraction plotted relative to DMSO control cells. Data represent the mean of two independent repeats run in triplicate ± SD. C, FaDu WT and KO cells treated with olaparib +/− AZD0156 were processed for flow cytometry at 24, 48, or 72 hours. For 24-hour samples, cell-cycle phase was determined on the basis of DNA content (blue, G1; yellow, S; red, G2M; and black, sub-G1). D, Cell-cycle histograms are shown for FaDu WT cells treated with olaparib +/− AZD0156 at 24, 48, or 72 hours.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    AZD0156 impairs olaparib-induced DNA damage repair in FaDu WT cells, resulting in cell death through apoptosis. A, γH2AX foci in green, and nuclear staining by Hoescht in blue (left). γH2AX foci formation was measured at 48 hours following olaparib and in combination with AZD0156 (30 nmol/L) in the FaDu WT cell line. The graph represents the percent of cells with γH2AX foci (green; right). Data are represented as the mean of three independent experiments conducted in triplicate +/− SEM. Cell lysates prepared from cells dosed with olaparib +/− AZD0156 were analyzed for pCHK1-S345 and γH2AX at 48 hours (right). B, FaDu WT cells were dosed with DMSO, 30 nmol/L AZD0156, or 3 μmol/L olaparib +/− 30 nmol/L AZD0156. After 48 hours, cells were processed, and the alkaline comet assay was conducted (left). Data are presented as the percent tail intensity of cells from a single experiment ± SEM (scatter plot), and as the mean fold increase in tail intensity relative to DMSO control cells across three independent experiments ± SEM (right). C, FaDu WT cells were treated with increasing doses of AZD0156 and olaparib and incubated with caspase-Glo reagent. Images of cells were captured on the IncuCyte every 4 hours. Apoptosis is reported relative to cell confluence. Data represent the mean of triplicate samples from a single experiment ± SEM.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    AZD0156 potentiates the effects of olaparib across a broad range of cancer cell lines in vitro. A, Example graphs of growth inhibition curves of cells dosed with 0 or 33 nmol/L AZD0156 +/− increasing doses of olaparib for 5 to 8 days depending on cell doubling rate. B, Cell number was determined using the sytox green assay. GI50 values were derived from growth inhibition curves generated in GraphPad Prism. GC; gastric cancer.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    In vivo antitumor efficacy of AZD0156 in patient-derived explants in combination with olaparib. In all studies when delivered in combination, olaparib is dosed first, followed 1 hour later by AZD0156. Adjacent to each efficacy figure (A+B), group plots demonstrate the growth of individual tumors over the study time frame. A, HBCx-10 patient-derived TNBC tumor explant (BRCA2 mut) grown subcutaneously and treated with olaparib (50 mg/kg oral days 1–5 each week for 7 weeks) or AZD0156 either alone or in combination (monotherapy, 20 mg/kg oral alternate day schedule; combination, 2.5 mg/kg orally on days 1–5 each week for 7 weeks; initial group sizes n = 8–10). B, HBCx-9 patient-derived TNBC tumor explant (BRCA2 WT) grown subcutaneously and treated with olaparib (50 mg/kg oral once daily) or AZD0156 either alone or in combination (monotherapy, 2.5 mg/kg oral on days 1–5 each week; combination, 5 mg/kg oral on days 1–3 each week; initial group sizes n = 10). PO, orally.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Assessment of pharmacodynamic biomarkers of ATM activity and DNA damage HBCx10 patient-derived TNBC xenograft models were dosed with vehicle, AZD0156 (2 mg/kg) once daily, olaparib (50 mg/kg) once daily, or olaparib + AZD0156 (once daily). Protein isolated from tumors derived from animals after 1 day of dosing was analyzed for pATM-S1981 expression by Western blotting (A) or PARylation by ELISA (B). For Western blotting analysis, protein expression was normalized to vinculin and the geometric mean of each animal group is presented relative to the geometric mean of the vehicle group ± SEM. C, Western blot analysis of γH2AX (geometric mean relative to vehicle groups ± SEM). D, Plasma pharmacokinetics was measured 1 hour after compound administration on day 1 and on day 14.

Tables

  • Figures
  • Additional Files
  • Table 1.

    Comparison of ATM inhibitor properties in cell assays.

    TargetKU559933 IC50 (μmol/L)KU60019 IC50 (μmol/L)AZD0156 IC50 (μmol/L)
    ATM (pATMS1981)1.13 (N = 222)0.15 (N = 223)0.00058 (N = 16)

Additional Files

  • Figures
  • Tables
  • Supplementary Data

    • Supplementary Data - Table S1. Mass Specrometer and UPLC system parameters; Table S2. Optimization parameters for mass spectrometry analysis; Figure S1.Spontaneous micronuclei formation with AZD0156; Figure S2. In vitro potentiation of AZD0156 and Olaparib across a gastric cell panel; Figure S3. In vitro washout experiments; Figure S4. In vivo anti-tumor efficacy of AZD0156 in patient-derived explant HBCx-9 in combination with olaparib; Figure S5. Individual animal bodyweights (g) of mice with HBCx-10 patient-derived breast tumour explant (BRCA-2 mut).
PreviousNext
Back to top
Molecular Cancer Therapeutics: 19 (1)
January 2020
Volume 19, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
Lucy C. Riches, Antonio G. Trinidad, Gareth Hughes, Gemma N. Jones, Adina M. Hughes, Andrew G. Thomason, Paul Gavine, Andy Cui, Stephanie Ling, Jonathan Stott, Roger Clark, Samantha Peel, Pendeep Gill, Louise M. Goodwin, Aaron Smith, Kurt G. Pike, Bernard Barlaam, Martin Pass, Mark J. O'Connor, Graeme Smith and Elaine B. Cadogan
Mol Cancer Ther January 1 2020 (19) (1) 13-25; DOI: 10.1158/1535-7163.MCT-18-1394

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
Lucy C. Riches, Antonio G. Trinidad, Gareth Hughes, Gemma N. Jones, Adina M. Hughes, Andrew G. Thomason, Paul Gavine, Andy Cui, Stephanie Ling, Jonathan Stott, Roger Clark, Samantha Peel, Pendeep Gill, Louise M. Goodwin, Aaron Smith, Kurt G. Pike, Bernard Barlaam, Martin Pass, Mark J. O'Connor, Graeme Smith and Elaine B. Cadogan
Mol Cancer Ther January 1 2020 (19) (1) 13-25; DOI: 10.1158/1535-7163.MCT-18-1394
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Antineoplastic Effects of a Novel CDK2/9 Inhibitor CYC065
  • MTX-23, a Novel PROTAC That Degrades AR-V7 and AR-FL
  • Glutaminase Inhibition Improves Efficacy of Immunotherapies
Show more Small Molecule Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement